ArticleThe World Allergy Organization journal2026
Long-term prophylaxis in hereditary angioedema: Real-world treatment patterns and healthcare resource utilization.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple non-androgen long-term prophylaxis (LTP) therapies have been approved in the United States to prevent hereditary angioedema (HAE) attacks. Real-world data on treatment compliance, healthcare resource utilization (HRU), and costs in this population are limited. Objective: Assess LTP treatment patterns, associated HRU, and costs in patients with HAE using a national claims database. Methods: Commercially insured patients from the IQVIA PharMetrics® Plus Closed Health Plan Claims Database (January 2016-September 2023) had ≥1 claim for non-androgen LTP, with ≥6 months of continuous enrollment pre-index and ≥12 months post-index (first LTP claim). Patient cohorts: no/minimal refill gaps, with refill gaps, or switchers. Annualized mean on-demand therapy claims, HRU, and costs were evaluated 12 months pre- and post-index. Results: A total of 328 patients were included in this analysis. Most patients (67%) had ≥1 post-index on-demand therapy claim. Mean (SD) annualized on-demand therapy doses pre- and post-LTP, respectively, were 20.8 (25.1) vs 12.4 (15.2) ( Conclusion: This study found that 55% of patients had refill gaps in LTP claims, discontinued, or switched LTP within a year of initiation. Even with use of LTP, on-demand treatment utilization remained present for over two-thirds of patients. Substantial increases in total HAE-related healthcare costs were driven by LTP pharmacy costs, without significant reductions in HRU. These findings highlight the importance of monitoring and optimizing treatments for those living with HAE and ensuring access to on-demand treatment for all as the foundation for HAE management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.